Sienna Biopharma Seeks To Convert Its Ch. 11 Case
Dermatology treatment developer Sienna Biopharmaceuticals Inc. asked a Delaware bankruptcy judge late Friday to convert its Chapter 11 case to a Chapter 7 liquidation as it no longer had its lenders'...To view the full article, register now.
Already a subscriber? Click here to view full article